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Abstract
Background: Hereditary non-polyposis colorectal cancer (HNPCC) is an autosomal dominant
disease with a high risk for colorectal and endometrial cancer caused by germline mutations in
DNA mismatch-repair genes (MMR). HNPCC accounts for approximately 2 to 5% of all colorectal
cancers. Here we present 6 novel mutations in the DNA mismatch-repair genes MLH1, MSH2 and
MSH6.
Methods: Patients with clinical diagnosis of HNPCC were counselled. Tumor specimen were
analysed for microsatellite instability and immunohistochemistry for MLH1, MSH2 and MSH6
protein was performed. If one of these proteins was not detectable in the tumor mutation analysis
of the corresponding gene was carried out.
Results: We identified 6 frameshift mutations (2 in MLH1, 3 in MSH2, 1 in MSH6) resulting in a
premature stop: two mutations in MLH1  (c.2198_2199insAACA [p.N733fsX745],
c.2076_2077delTG [p.G693fsX702]), three mutations in MSH2 (c.810_811delGT [p.C271fsX282],
c.763_766delAGTGinsTT [p.F255fsX282], c.873_876delGACT [p.L292fsX298]) and one mutation
in MSH6 (c.1421_1422dupTG [p.C475fsX480]). All six tumors tested for microsatellite instability
showed high levels of microsatellite instability (MSI-H).
Conclusions: HNPCC in families with MSH6 germline mutations may show an age of onset that
is comparable to this of patients with MLH1 and MSH2 mutations.
Background
Hereditary nonpolyposis colorectal cancer (HNPCC) is
characterized by very high risk for colorectal cancer [1]. In
addition, endometrial and ovary cancer risk as well as risk
for tumors of the ureter, renal pelvic and small intestine is
increased. Germline mutations of MLH1  and  MSH2
account for 70% of all HNPCC cases [2]. Approximately
5–10% of HNPCC families carry a germline mutation in
the MSH6 gene [3-5]. Here we report six germline muta-
tions in the mismatch-repair genes MLH1,  MSH2  and
MSH6, that to our best knowledge have not been
described (Medline and HNPCC mutation database http:/
/www.nfdht.nl.
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Methods
This study was approved by the ethical committee of the
Medical Faculty of the Ruhr-University Bochum. All
patients underwent interdisciplinary counselling by a
geneticist, clinician and psychologist. Patients included in
this study fulfilled the Amsterdam or Bethesda criteria [1].
Substantial pedigree information moreover including the
revised Bethesda criteria [6] is given in table 1. After given
informed consent blood samples were drawn for genetic
testing. Genomic DNA was extracted using standard pro-
tocol [7].
Formalin fixed and paraffin embedded tumor tissues were
obtained from different primary pathologists and sent
upon request to the local reference pathology of the
Familial Colorectal Cancer Center of the Ruhr University
Bochum. Tumors were reexamined for histomorphologi-
cal HNPCC features, immunohistochemical MMR repair
protein expression and microsatellite instability.
Microsatellite Analysis
Tumor and surrounding normal tissue were microdis-
sected by a skilled pathologist. Tumor cell cellularity was
at least 70%. DNA was isolated with the QIAamp DNA
Mini Kit (Qiagen, Hilden, Germany). Microsatellite mark-
ers BAT-25, BAT-26, D5S346, D17S250, D2S123 and
BAT-40 were amplified. The markers included the NIH
reference panel according to the international guidelines
for the evaluation of MSI in colorectal cancer (Boland et
al., 1998). Primer sequences are available on request.
Tumors were classified as having high grade microsatellite
instability (MSI-H) if at least 30% of the markers showed
instabilities. Microsatellite-PCR reactions were performed
in 96-well microtiter plates, in 20 mmol/L Tris-HCl, pH
8.4, 5 mmol/L KCl, 1.5 mmol/L MgCl2, 100 ng of each
primer, 200 mmol/L dNTPs, 60 mmol/L TMAC (Sigma,
Taufkirchen, Germany), 1.5% formamide, 2 ml DNA tem-
plate (tumor or normal tissue), and 1.5 units Taq DNA
polymerase (Gibco BRL, Karlsruhe, Germany), in a final
volume of 15 ml. Reactions were performed in a Hybaid
Touchdown temperature cycler (MWG-Biotech, Ebers-
berg, Germany), for 40 cycles of 94°C for 15 seconds, dif-
ferent annealing temperatures for each marker for 30
seconds, and 72°C for 30 seconds, and a final extension
at 72°C for 5 minutes. BAT-25, BAT-26, BAT-40 and
D2S123 were amplified with an annealing temperature of
60°C, whereas D5S346 was performed at 58°C and
D17S250 at 53°C. PCR products were separated on 6%
polyacrylamide, 8 mol/L urea gels and DNA fragments
were visualized by silver staining.
Table 1: Pedigree information and clinical diagnosis of the investigated patients
Patient ID Clinical diagnosis Manifestation patient (age of diagnosis) Manifestation family members (age of diagnosis)
0546-2 AMS II CRC (32) Mother: adenocarcinoma in the small pelvis (39)
brother of mother: CRC (35)
sister of mother: endometrial carcinoma (35)
sister of mother. endometrial carcinoma (53), CRC (54)
grandfather: CRC (42)
sister of grandfather: CRC (66)
sister of grandfather: CRC (48)
brother of grandfather: gastric cancer (34)
0699-3 B2, 3 and 4/Br1, 2, and 4 CRC (40; 53) Mother: breast cancer (45)
grandmother: CRC (70)
cousin of mother: endometrial carcinoma (45)
cousin of mother: CRC (40); endometrial carcinoma (48)
daughter of cousin: CRC (33)
0545-0 B2,3 and 4/Br1, 2 and 4 CRC (29) Father: CRC (52; 55; 58)
0729-5 AMS I CRC (44; 46; 54) Father: CRC (55)
Grandfather CRC (unknown age)
0660-6 AMS I CRC (42) mother: CRC (30 and 57)
grandmother: endometrial carcinoma (47), lung cancer (48)
sister of grandmother: CRC (51)
sister of grandmother: endometrial carcinoma (50)
brother of grandmother: CRC (53 and 65)
0531-X B7/Br1 colon adenoma (39; 41) Sister: colon adenoma (41)
Grandmother: CRC (40)
AMS I Amsterdam criteria; AMS II Amsterdam criteria revised; B Bethesda criteria, Br revised Bethesda criteria; CRC colorectal cancerBMC Medical Genetics 2004, 5 http://www.biomedcentral.com/1471-2350/5/16
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Immunohistochemistry
For immunohistochemistry 3 µm thick sections of forma-
lin fixed paraffin embedded tumor tissue were mounted
on poly-L-lysine capillary slides and dried overnight at
37°C. Paraffine sections were dewaxed with xylene, rehy-
drated in a graded series of alcohol and finally washed in
Tris-HCl (pH 7.6) for 10 min. The following steps were
performed at room temperature in an automated staining
system (TechMate 500, Dako, Glostup, Denmark). To
avoid unspecific staining, sections were blocked with
buffer 1 (Dako) for 5 min prior to incubation with the pri-
mary antibody at the appropriate dilution in blocking
buffer (Zytomed, USA) for 30 min at room temperature.
As primary antibodies mouse monoclonal antibodies for
MLH1 (BD Biosciences, 1:20), MSH2 (BD Biosciences,
1:20) and MSH6 (BD Biosciences, 1:50) were applied.
After several rinses in buffer (Buffer Kit, Dako) the immu-
noreaction was demonstrated using the APAAP Kit
(Dako) according to the specifications of the manufac-
turer. Fast Red (Dako) was used as alkaline-phosphatase
substrate. Finally sections were rinsed in distilled water
and counterstained with Mayer's haematoxylin (Dako).
Staining was considered only informative when there was
normal nuclear staining in adjacent non-neoplastic cells,
which served as internal control. Less than <1% of stained
tumor cells was considered as loss of expression of a MMR
protein, whereas 10–100% of stained tumor cells was
considered as normal staining.
Mutation analysis of MLH1, MSH2 and MSH6 genes
Exons and flanking intronic regions were sequenced by
using ABI standard protocols. Primers are available on
request. For all systems forward and reverse strands were
sequenced. Sequencing was performed corresponding to
the immunohistochemical result. If MSH2 staining was
reduced or negative and MSH6 staining negative as well,
the MSH2 gene was sequenced at first. Pathogenic rele-
vant mutations were sequenced twice and confirmed in a
second blood sample of the patient. Mutations were
named according to the nomenclature of den Dunnen
and Antonarakis [8].
Results and discussion
All tumor specimens of the investigated patients showed
MSI in at least 2 of five tested loci and therefore were clas-
sified as MSI-H. Tumor tissue of all patients was
immunohistochemically stained (table 2).
Person 0546-2 showed no MLH1 expression in the tumor
compared to normal tissue. The pedigree fulfilled the
Amsterdam II criteria. Sequencing analysis revealed the
germline mutation c.2198_2199insAACA in exon 19 of
MLH1. This frameshift mutation results in a premature
stop at codon 746. Sequencing of the whole coding
sequence including exon-intron boundaries showed no
other abnormalities. Moreover similar mutations near to
nucleotide position 2198 of MLH1 have been described
earlier as pathogenic.
Patient 0699-3 presented with two metachronous colon
cancers at the age of 40 and 53 years (criterion 2 of the old
[1] and revised [6] Bethesda guidelines). The tumor tissue
of patient 0699-3 showed the MSI-H phenotype. The
MLH1 protein was not detectable by immunohistochem-
Table 2: Microsatellite status and immunohistochemical staining of tumor tissue, result of sequencing analysis in all investigated 
patients.
Patient ID MS-status Immunohistochem
ical staining of 
tumor tissue
Gene Exon Mutation Length of 
predicted protein 
after truncation
0546-2 MSI-H MLH1 neg, MSH2 
pos, MSH6 pos
MLH1 19 c.2198_2199insAA
CA 
[p.N733fsX745]
Cd 745
0699-3 MSI-H MLH1 neg, MSH2 
pos, MSH6 pos
MLH1 18 c.2076_2077delT
G [p.G693fsX702]
Cd 702
0545-0 MSI-H MSH2 neg, MSH6 
neg, MLH1 pos
MSH2 5 c.810_811delGT 
[p.C271fsX282]
Cd 281
0729-5 MSI-H MSH2 red, MSH6 
neg, MLH1 pos
MSH2 4 c.763_766delAGT
GinsTT 
[p.F255fsX282]
Cd 282
0660-6 MSI-H MSH2 neg, MSH6 
neg, MLH1 pos
MSH2 5 c.873_876delGAC
T [p.L292fsX298]
Cd 299
0531-X MSI-H MSH2 pos, MSH6 
neg, MLH1 pos.
MSH6 4 c.1421_1422dupT
G [p.C475fsX480]
Cd 480
Cd codon, MS = microsatellite status, pos = staining of >10% tumor cells, red = staining of 1–10% tumor cells, neg = staining of <1% of tumor cells, 
n.d. = not doneBMC Medical Genetics 2004, 5 http://www.biomedcentral.com/1471-2350/5/16
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istry and a germline mutation c.2076_2077delTG in
codon 693 of the MLH1 gene was detected. The resulting
protein is predicted to consist of 702 amino acids.
Patient 0545-0 developed left sided colon cancer at the
age of 29. The family history fulfilled criterion 2, 3 and 4
of the Bethesda guidelines respectively criterion 1, 2 and 4
of the revised Bethesda criteria. Tumor tissue showed no
MSH2 expression and stained negative for MSH6. The lat-
ter finding is likely caused by the reported heterodimer
formation between MSH2 and MSH6 [9]. Microsatellite
analysis of the tumor tissue from this patient revealed a
MSI-H status. Sequencing revealed the mutation
c.810_811delGT in the MSH2 gene. This deletion of two
nucleotides leads to a truncation of the MSH2 protein
after 281 amino acids.
In patient 0729-5 and 0660-6 we identified the mutation
c.763_766delAGTGinsTT [p.F255fsX282] and
c.873_876delGACT [p.L292fsX298] respectively in the
MSH2 gene. Tumor tissue of patient 0729-5 staining pos-
itive in 1–10% tumor cells using the MSH2 antibody. The
tumor of 0660-6 was immunohistochemically deficient
for the MSH2 protein. Microsatellite analysis of tumor tis-
sue of both patients showed MSI-H. The pedigrees of both
patients match the Amsterdam I criteria. The immunohis-
tochemical staining of patient 0660-6 is shown in Fig. 1.
MLH1 staining Figure 1
MLH1 staining Patient 0660-6: Mucinous adenocarcinoma of the colon with a strong nuclear staining (red staining product) of 
the tumor cells (arrows) for MLH1 (1).BMC Medical Genetics 2004, 5 http://www.biomedcentral.com/1471-2350/5/16
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Patient 0531-X had tubulovillous adenoma at the age of
39. Colonoscopy was performed annually and the patient
developed seven adenomas within a two years follow-up
period. The sister presented with an adenoma of
unknown histology at the age of 41. The 40 year old
grandmother died of colorectal cancer. So far no female
developed endometrial cancer. This pedigree fulfilled cri-
terion 7 of the Bethesda guidelines [1]. Criterion 1 of the
revised Bethesda guidelines is met. Tumor tissue of
patient 0531-X revealed MSI-H. Firstly, immunohisto-
chemistry of MLH1 and MSH2 was performed only and
revealed normal expression of MLH1 and MSH2 protein
in the tumor tissue. In addition, immunohistochemistry
of MSH6 was done and showed loss of MSH6 protein
expression. The frameshift mutation c.1421_1422dupTG
[p.C475fsX480] in the MSH6  gene was detected. The
father of the index patient was not affected by HNPCC-
associated cancers and is currently aged 65. Although the
published data supports the notion of a later onset of
disease in HNPCC families carrying an MSH6 mutation,
this was not the case in our family. The index patient and
her sister started to develop adenomas by the age of 39
and 41 years respectively. Moreover the paternal grand-
mother died of colorectal cancer at age 40. These findings
are comparable to data for MLH1 and MSH2 mutation
positive individuals with HNPCC.
Conclusions
Our phenotype data imply that HNPCC associated with
MSH6 gene mutations may show an age of onset that is
MSH2 staining Figure 2
MSH2 staining Patient 0660-6: Mucinous adenocarcinoma of the colon with a negative staining of the tumor cells for MSH2. As 
an internal positive control, lymphocytes (arrowheads) in an adjacent lymph follicle show a positive nuclear staining for MSH2BMC Medical Genetics 2004, 5 http://www.biomedcentral.com/1471-2350/5/16
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comparable to this of patients with MLH1  and  MSH2
mutations. Therefore, screening recommendations
should not be loosened for families with MSH6  gene
mutations.
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